Key facts
- Holo Bio’s last known valuation is $5.5M (Feb 2025).
- It has raised $1.6M; the latest was Seed Round ($1.6M) in Feb 2025.
- Notable investors include Genesia Ventures, Kyoto University Innovation Capital, Chushin Venture Capital, Senshu Ikeda Capital, Will Capital Management.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Holo Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Holo Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Holo Bio
Developer of a new organism breeding technology designed to solve mankind's food problems. The company focuses on PA productivity of the intestinal bacterium GI35 strain that was discovered in the fish species endemic to Lake Biwa, Isaza, and supplies EPA from the body of fish inhabited by bacteria, enabling society with plant fiber that was previously inedible and now eatable.
- Sector
- Healthcare
- HQ
- Kyoto, Japan
- Founded
- 2020
- Website
- holo-bio.com/
- Ownership
- Privately Held (backing)
Holo Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Holo Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Holo Bio in its N-PORT filings yet. We sweep new filings monthly.